Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Graham

Showing results (1421-1430 of 1,460) with videos related to

Pageof 146
Sort By:
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science (New York, N.Y.)|August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccineRobert A Seder, Lee-Jah Chang, Mary E Enama, et al.
Science (New York, N.Y.)|August 1, 2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodiesWilton B Williams, Hua-Xin Liao, M Anthony Moody, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2021
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variantsLingshu Wang, Tongqing Zhou, Yi Zhang, et al.
Biorxiv : the Preprint Server for Biology|November 3, 2021
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airwayMatthew Gagne, Kizzmekia S Corbett, Barbara J Flynn, et al.
Emerging Infectious Diseases|July 5, 2020
Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020Benjamin D Hallowell, Christina M Carlson, Jesica R Jacobs, et al.
Pageof 146

Showing results (1421-1430 of 1,460) with videos related to

Sort By:
Pageof 146
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science (New York, N.Y.)|August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccineRobert A Seder, Lee-Jah Chang, Mary E Enama, et al.
Science (New York, N.Y.)|August 1, 2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodiesWilton B Williams, Hua-Xin Liao, M Anthony Moody, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2021
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variantsLingshu Wang, Tongqing Zhou, Yi Zhang, et al.
Biorxiv : the Preprint Server for Biology|November 3, 2021
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airwayMatthew Gagne, Kizzmekia S Corbett, Barbara J Flynn, et al.
Emerging Infectious Diseases|July 5, 2020
Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020Benjamin D Hallowell, Christina M Carlson, Jesica R Jacobs, et al.
Pageof 146